Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2392-2396

  Gauthier, Timothy P ^a   Wolowich, William R ^a   Reddy, Arathi ^b   Cano, Ennie ^c   Abbo, Lilian ^d   Smith, Laura B ^c  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b BAPTIST HOSPITAL OF MIAMI   (United States)

^c JACKSON MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG OVERDOSE; FEMALE; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY INJURY; LENGTH OF STAY; MALE; MORTALITY; NEPHROTOXICITY; OBESITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; COLISTIN; DRUG DOSAGE CALCULATIONS; FEMALE; GRAM-NEGATIVE BACTERIA; HOSPITAL MORTALITY; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84860176935     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00028-12     Document Type: Article

References (28)

1. Bellomo R, et al. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8:R204-R212.
2. Couet W, Grégoire N, Marchand S, Mimoz O. 2012. Colistin pharmacokinetics: the fog is lifting. Clin. Microbiol. Infect. 18:30-39.
3. Demirovic JA, Pai AB, Pai MP. 2009. Estimation of creatinine clearance in morbidly obese patients. Am. J. Health Syst. Pharm. 66:642-648.
4. DeRyke CA, Crawford AJ, Uddin N, Wallace MR. 2010. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob. Agents Chemother. 54:4503-4505.
5. Doshi NM, Mount KL, Murphy CV. 2011. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 31:1257-1264.
6. Evans ME, Feola DJ, Rapp RP. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967. (Pubitemid 29420995)
7. Falagas ME, Karageorgopoulos DE. 2010. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375:248-251.
8. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10:R27.
9. Falagas ME, et al. 2010. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 35:194-199.
10. Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241.
11. Garonzik SM, et al. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294.
12. Hartzell JD, et al. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724-1728.
13. JHP Pharmaceuticals, LLC. 2011. Coly-Mycin M parenteral (colistimethate for injection, USP) package insert. JHP Pharmaceuticals, LLC, Parsippany, NJ.
14. Kellum JA, Bellomo R, Ronco C. 2008. Definition and classification of acute kidney injury. Nephron Clin. Pract. 109:c182-c187.
15. Kim J, Lee K-H, Yoo S, Pai H. 2009. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int. J. Antimicrob. Agents 34:434-438.
16. Koch-Weser J, et al. 1970. Adverse effects of sodium colistimethate. Ann. Intern. Med. 72:857-868.
17. Kwon J-A, et al. 2010. Predictors of acute kidney injury associated with intravenous colistin treatment. Int. J. Antimicrob. Agents 35:473-477.
18. Li J, et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
19. Lim LM, et al. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30:1279-1291.
20. McKenzie C. 2011. Antibiotic dosing in critical illness. J. Antimicrob. Chemother. 66(Suppl 2):ii25-ii31.
21. Nation RL, Li J. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543.
22. Pai MP, Bearden DT. 2007. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27:1081-1091.
23. Pogue JM, et al. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin. Infect. Dis. 53:879-884.
24. Pogue JM, Marchaim D, Kaye D, Kaye KS. 2011. Revisiting "older"antimicrobials in the era of multidrug resistance. Pharmacotherapy 31:912-921.
25. Salazar DE, Corcoran GB. 1988. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am. J. Med. 84:1053-1060.
26. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. 2011. Renal and neurological side effects of colistin in critically ill patients. Ann. Intensive Care 1:14.
27. WHO 2004, posting date. World Health Organization body mass index classification. World Health Organization, Geneva, Switzerland. http://apps.who.int/bmi/index.jsp?introPage=intro-3.html.
28. X-Gen Pharmaceuticals, Inc. 2010. Colistimethate (colistin) package insert. X-Gen Pharmaceuticals, Inc., Big Flats, NY.